• 2025: Addressing the Rising Threat of Whooping Cough

  • Jan 27 2025
  • Length: 7 mins
  • Podcast

2025: Addressing the Rising Threat of Whooping Cough

Listen for free

View show details

  • Summary

  • Watch on YouTube

    In an exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest milestone—a world-first pivotal Phase 3 human challenge trial for a whooping cough (pertussis) vaccine candidate. Mo delves into why ILiAD is leading this groundbreaking initiative, the trial’s key objectives, and its significance for hVIVO’s expanding portfolio. He also provides insight into the increasing global burden of pertussis and hVIVO’s readiness to conduct bacterial challenge trials at its state-of-the-art Canary Wharf facility.
    Show more Show less
Show more Show less

What listeners say about 2025: Addressing the Rising Threat of Whooping Cough

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.ca reviews

Amazon Reviews
No reviews are available